|Videos|January 18, 2023

Dr. Berg highlights key ongoing trials in urothelial cancer

Several treatments are being explored across these trials, including pembrolizumab, nivolumab, enfortumab vedotin, durvalumab, avelumab, and cabozantinib.

Stephanie Berg, DO, highlights key ongoing trials in advanced/metastatic urothelial cancer, including EV-302 (NCT04223856), NILE (NCT03682068) CheckMate-901 (NCT03036098), and MAIN-CAV (NCT05092958).Berg is an instructor of medicine, Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME